Compare LBRX & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | LWLG |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 578.6M |
| IPO Year | 2025 | N/A |
| Metric | LBRX | LWLG |
|---|---|---|
| Price | $19.89 | $3.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | 531.1K | ★ 2.1M |
| Earning Date | 02-15-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $100,605.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.36 | $0.79 |
| 52 Week High | $23.15 | $6.26 |
| Indicator | LBRX | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.33 |
| Support Level | N/A | $3.09 |
| Resistance Level | N/A | $3.45 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 0.00 | 91.81 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.